Welcome to the University of Maryland Marlene and Stewart Greenebaum Cancer Center, a premier cancer and research treatment center at the University of Maryland, Baltimore. The cancer center is a joint program of the University of Maryland School of Medicine and the University of Maryland Medical System. UMGCC was named a National Cancer Institute (NCI)-designated cancer center in 2008, one of only 64 such centers in the country. In 2012, UMGCC was ranked #11 out of 900 cancer programs in the country by U.S. News and World Report.
At UMGCC, we pride ourselves in providing outstanding patient care, with an emphasis on the multidisciplinary approach to diagnosis and treatment. Teams consisting of medical oncologists, surgeons, radiation oncologists, pathologists, radiologists, nurses and others work together to bring compassionate and cutting-edge care to our patients.
Activities of the cancer center include basic and translational cancer research, student and house officer teaching, and a strong focus on new therapies in both an inpatient 46-bed unit and an outpatient setting, the Roslyn and Leonard Stoler Pavillion.
Translational research is a top priority, with scientists working together with clinicians to facilitate the translation of scientific discoveries into clinical advances. One outstanding example of the research at UMGCC is the work of Dr. Angela Brodie who developed the first aromatase inhibitor here at Maryland. These drugs have been the most important recent advance in the treatment of breast cancer, dramatically improving outcomes for women worldwide. Dr. Brodie has been honored for this pioneering work by the prestigious Kettering and Landon prizes.
Cancer research funding at UMGCC has grown by 353% since 2002 — from $19.4 to $68.5 million, continuing to drive scientific discovery by our cancer experts, all of whom are on the faculty of the University of Maryland School of Medicine. The center is a strong participant in new drug development and trials, and is a member of several national cooperative groups.
We have strong translational research programs in experimental therapeutics, hormone responsive cancers, molecular and structural biology, tumor immunology and immunotherapy, and population science. UMGCC is a leader in addressing cancer disparities, with research focused on improving access to care and treatment outcomes for minorities, who represent 36 percent of the patients in our clinical trials, compared to less than 2 percent nationally.
We think this environment is an exceptional place for fellowship training. At UMGCC, we offer the combination of superb clinical trialists, dedicated clinician-educators and cutting-edge basic science researchers in state-of-the-art facilities, making our institution an outstanding place for oncologists-in-training.
Thank you for your interest in our institution, and we look forward to your visit.
Kevin J. Cullen, M.D.
Marlene and Stewart Greenebaum Distinguished Professor of Oncology
University of Maryland Greenebaum Cancer Center